Search Results - "Meadows Shropshire, Stephanie"

Efficacy and Safety of Abatacept in Lupus Nephritis: A Twelve‐Month, Randomized, Double‐Blind Study by Furie, Richard, Nicholls, Kathy, Cheng, Tien‐Tsai, Houssiau, Frederic, Burgos‐Vargas, Ruben, Chen, Shun‐Le, Hillson, Jan L., Meadows‐Shropshire, Stephanie, Kinaszczuk, Michael, Merrill, Joan T.

“…Objective To compare the efficacy and safety of intravenous (IV) abatacept, a selective T cell costimulation modulator, versus placebo for the treatment of…”
Get full text

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans by Merali, Samira, Wang, Zhaoqing, Frost, Charles, Callejo, Mario, Hedrick, Michael, Hui, Lester, Meadows Shropshire, Stephanie, Xu, Ke, Bouvier, Michel, DeSouza, Mary M., Yang, Jing

“…BMS-986120 is a novel first-in-class oral protease-activated receptor 4 (PAR4) antagonist exhibiting robust antithrombotic activity that has shown low bleeding…”
Get full text

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032) by Callahan, Margaret, Amin, Asim, Kaye, Frederic J, Morse, Michael A, Taylor, Matthew H, Peltola, Katriina J, Sharma, Padmanee, O'Reilly, Eileen M, Meadows Shropshire, Stephanie, O'Brien, Shaun, Tschaika, Marina, Le, Dung T

“…BackgroundPancreatic cancer is one of the deadliest cancer types and represents a major unmet medical need. CheckMate 032 investigated safety and efficacy of…”
Get full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial by Paz-Ares, Luis, Ciuleanu, Tudor-Eliade, Cobo, Manuel, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurelia, Sakai, Hiroshi, Lingua, Alejo, Salman, Pamela, Souquet, Pierre-Jean, De Marchi, Pedro, Martin, Claudio, Pérol, Maurice, Scherpereel, Arnaud, Lu, Shun, John, Thomas, Carbone, David P, Meadows-Shropshire, Stephanie, Agrawal, Shruti, Oukessou, Abderrahim, Yan, Jinchun, Reck, Martin

“…First-line nivolumab plus ipilimumab has shown improved overall survival in patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate…”
Get full text

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants by Merali, Samira, Wang, Zhaoqing, Frost, Charles, Meadows-Shropshire, Stephanie, Hawthorne, Dara, Yang, Jing, Seiffert, Dietmar

“…BMS-986141 is a novel, oral, protease-activated, receptor 4 (PAR4)-antagonist that exhibited robust antithrombotic activity and low bleeding risk in…”
Get full text

Adverse events and clinical outcomes in patients treated with PD-(L)1 blockade for advanced non-small-cell lung cancer by Zhang, Yan, Doran, Charlotte, Le, Trong Kim, Dreyfus, Brian, Kola, Nina, Sylvester, Brooke E, Lal, Lincy, Penrod, John R, Meadows Shropshire, Stephanie

“…To describe, in patients with advanced/metastatic non-small-cell lung cancer, the relationship between baseline immunosuppressive drug (ISD)/corticosteroid…”
Get full text

Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA by Reck, Martin, Ciuleanu, Tudor-Eliade, Dols, Manuel Cobo, Schenker, Michael, Zurawski, Bogdan, Menezes, Juliana, Richardet, Eduardo, Bennouna, Jaafar, Felip, Enriqueta, Juan-Vidal, Oscar, Alexandru, Aurella, Sakai, Hiroshi, Scherpereel, Arnaud, Lu, Shun, John, Thomas, Carbone, David Paul, Meadows-Shropshire, Stephanie, Yan, Jinchun, Paz-Ares, Luis G.

“…Abstract only 9501 Background: NIVO + IPI was shown to improve overall survival (OS) and durability of response vs chemo in 1L advanced NSCLC in CheckMate 227…”
Get full text

Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results by Sharma, Padmanee, Siefker-Radtke, Arlene, de Braud, Filippo, Basso, Umberto, Calvo, Emiliano, Bono, Petri, Morse, Michael A, Ascierto, Paolo A, Lopez-Martin, Jose, Brossart, Peter, Rohrberg, Kristoffer, Mellado, Begoña, Fischer, Bruce S, Meadows-Shropshire, Stephanie, Abdel Saci, Callahan, Margaret K, Rosenberg, Jonathan

“…CheckMate 032 is an open-label, multicohort study that includes patients with unresectable locally advanced or metastatic urothelial carcinoma (mUC) treated…”
Get full text

Perioperative Nivolumab in Resectable Lung Cancer by Cascone, Tina, Awad, Mark M., Spicer, Jonathan D., He, Jie, Lu, Shun, Sepesi, Boris, Tanaka, Fumihiro, Taube, Janis M., Cornelissen, Robin, Havel, Libor, Karaseva, Nina, Kuzdzal, Jaroslaw, Petruzelka, Lubos B., Wu, Lin, Pujol, Jean-Louis, Ito, Hiroyuki, Ciuleanu, Tudor-Eliade, de Oliveira Muniz Koch, Ludmila, Janssens, Annelies, Alexandru, Aurelia, Bohnet, Sabine, Moiseyenko, Fedor V., Gao, Yang, Watanabe, Yasutaka, Coronado Erdmann, Cinthya, Sathyanarayana, Padma, Meadows-Shropshire, Stephanie, Blum, Steven I., Provencio Pulla, Mariano

“…In a randomized trial of perioperative nivolumab as compared with chemotherapy, 18-month event-free survival was 70% in the nivolumab group and 50% in the…”
Get full text

Sample size and power determination for detecting interactions in mixtures of chemicals by Meadows-Shropshire, S.L, Gennings, C, Carter, W.H. Jr

“…In the analysis of mixtures of drugs/chemicals it is often of interest to test for the presence of interaction. If the hypothesis of no interaction…”
Get full text

Analysis of Mixtures of Drugs/Chemicals along a Fixed-Ratio Ray without Single-Chemical Data to Support an Additivity Model by Meadows-Shropshire, Stephanie L., Gennings, Chris, Carter, W. Hans, Simmons, Jane Ellen

“…This article presents and illustrates an approach to designing and analyzing studies involving mixtures/combinations of drugs or chemicals along fixed-ratio…”
Get full text